New U.S. patent broadens Cytori Therapeutics' portfolio covering adipose-derived cell therapies

Cytori Therapeutics (NASDAQ:CYTX) today received U.S. Patent No. 7,651,684 (the ‘684 patent) which covers the Company’s methods for delivering adipose-derived stem and regenerative cell-enriched fat grafts into patients. The ‘684 patent specifically covers cell-enriched fat grafts to treat soft-tissue defects and urinary incontinence. In addition, the ‘684 patent covers methods for delivering cell-enriched fat grafts to a patient’s breast, wrinkles, lips, under the eyes, cheeks, chin, and other parts of the body.

“Today’s announcement broadens our current expansive patent portfolio covering adipose-derived cell therapies. The patent covers many significant applications for stem and regenerative cell-enriched fat grafting, allowing us to freely develop future generation therapeutics and pursue solutions for patients with unmet medical needs in tissue damage indications, including breast reconstruction”

“Today’s announcement broadens our current expansive patent portfolio covering adipose-derived cell therapies. The patent covers many significant applications for stem and regenerative cell-enriched fat grafting, allowing us to freely develop future generation therapeutics and pursue solutions for patients with unmet medical needs in tissue damage indications, including breast reconstruction,” said Christopher J. Calhoun, CEO of Cytori Therapeutics.

Within the Cytori family of products, the Company markets the Celution® 800/CRS System that creates adipose tissue-derived stem and regenerative cell-enriched autologous fat grafts, in the EU and elsewhere throughout the world. The ‘684 patent is designed to protect the Celution® 800/CRS System, as well as future generations of the device, when approved for marketing and sale in the U.S.

The ‘684 patent expands upon the Company’s previously issued U.S. Patent No. 7,429,488 relating to automated methods of creating cell-enriched fat grafts. Cytori Therapeutics' intellectual property portfolio currently includes 19 issued U.S. and international patents and 100 pending applications worldwide relating to the devices, methods and uses of adipose-derived stem and regenerative cells.